Contraception - Update and trends

Journal fur Reproduktionsmedizin und Endokrinologie

Volumn 4, Issue 6, 2007, Pages 337-357

  Rabe, Thomas ^a,b  

^a Heidelberg Medical School   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Contraception; Family planning; Female; Fertilisation; Fertility control; Implantation; Male; Ovulation; Spermatogenesis

Indexed keywords

ADIANA; CARRAGEENAN; CELLULOSE SULFATE; CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESSURE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FIDENCIA; GESTAGEN; LEVONORGESTREL; MEMBRANE ANTIGEN; MEPACRINE; MESTRANOL PLUS NORETYNODREL; MICROBICIDE; MIFEPRISTONE; NOMEGESTROL; OOCYTE ANTIGEN; ORAL CONTRACEPTIVE AGENT; OVABLOC; PROGESTERONE RECEPTOR MODULATOR; SPERMATOCYTE ANTIGEN; SPERMICIDAL AGENT; STEROID; SYNTHEX; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAZ;

ACNE VULGARIS; AMENORRHEA; BIRTH CONTROL; BLEEDING; BODY WEIGHT; BONE DENSITY; BREAST CANCER; BREAST FEEDING; CARDIOVASCULAR RISK; CONDOM; CONTRACEPTION; DEPRESSION; DRUG DOSE REDUCTION; DYSMENORRHEA; ENDOMETRIUM CANCER; FAMILY PLANNING; FEMALE STERILIZATION; FERTILIZATION; FRACTURE; GENETIC RISK; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCONTRACEPTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LIVER CANCER; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; OLIGOMENORRHEA; ORAL CONTRACEPTION; OVARY CANCER; OVULATION; OVULATION INHIBITION; PREMENSTRUAL SYNDROME; REVIEW; RISK; SAFE SEX; SEXUALLY TRANSMITTED DISEASE; SPERMATOGENESIS; SPERMATOZOON MIGRATION; THROMBOPHILIA; UTERINE CERVIX CANCER; UTERINE TUBE LIGATION; VAGINA RING; VAGINAL HYSTERECTOMY; VASECTOMY;

EID: 37249017441     PISSN: 18102107     EISSN: 18109292     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. D'Arcangues C. Future methods of fertility regulation. Training in Reproductive Health Research. World Health Organization, Geneva, 2006. http://www.gfmer.ch/Medical_education_En/PGC_RH_2006/pdf/ Future_Methods_Darcangues_2006.pdf
2. Petitti D. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443-50.
3. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2007; (1): CD004425.
4. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. Clin Psychiatry 1997: 589 (Suppl 14): 4-10.
5. Freeman EW, Halbreich U. Premenstrual syndromes. Psychopharmacol Bull 1998: 34: 291-305.
6. Tucker VS, Whalen RE. Premenstrual syndrome. Int J Psychiatry Med 1991; 21: 311-41.
7. Lin J, Thompson DS. Treating premenstrual dysphoric disorder using serotonin agents. J Womens Health Gend Based Med 2001; 10: 745-50.
8. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; (1): CD003987.
9. Oral contraceptive prescribing: should body weight influence choice of pill? Questions and Answers with Associate Editor Mitchell D. Creinin, MD. The Contraception Report 14; 4: 11-2, 15.
10. Ruffing JA, Nieves JW, Zion M, Tendy S, Garrett P, Lindsay R, Cosman F. The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets. Nutr Metab (Lond) 2007; 4: 17.
11. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474-82.
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
13. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-32.
14. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 2005; 16: 1059-63.
15. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MRE, Hopper JL, Whittemore AS for the Breast Cancer Family Registry. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 350-6.
16. Paul CD, Skegg DCG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: A national study. Br Med J 1986; 293: 723-5.
17. Oral-contraceptive use and the risk of breast cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1986; 315: 405-11.
18. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: Possible effect of formulation and age at use. Lancet 1983; 22: 926-9.
19. Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986; 68: 863-8.
20. Olsson H, Olsson ML, Moeller TR, Ranstam J, Holm P. Oral contraceptive use and breast cancer in young women in Sweden. Lancet 1985; 1: 748-9.
21. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987; 56: 653-60.
22. Huggins GR, Zucker PF. Oral contraceptives and neoplasia: 1987 update. Fertil Steril 1987; 47: 733-61.
23. McPherson K, Drife JO. The pill and breast cancer: why the uncertainty? Br Med J 1986; 293: 709-10.
24. Schlesselman JJ, Stadel BV, Murray P, Lai S. Breast cancer in relation to early use of oral contraceptives. No evidence of a latent effect. JAMA 1988; 259: 1828-33.
25. Hennekens CH, Speizer FE, Lipnick RJ, Rosner B, Bain C, Belanger C, Stampfer MJ, Willett W, Peto R. A case-control study of oral contraceptive use and breast cancer. J Natl Cancer Inst 1984; 72: 39-42.
26. Wingo PA, Harland A, Marchbanks PA, Whiteman MA, Hsia J, Mandel MG, Peterson HB, Ory HW. Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol 2007; 110: 793-8.
27. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80: 708-14.
28. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316: 650-5.
29. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94: 32-8.
30. Greer JB, Modugno F, Allen GO, Ness RB. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol 2005; 105: 731-40.
31. Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 2007; 109: 597-607.
32. Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 424-8.
33. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, Struewing JP, Friedman E, Piura B; National Israel Ovarian Cancer Study Group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-40.
34. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 2005; 166: 277-97.
35. Smith JS, Bosetti C, Muñoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW; IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431-9.
36. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481-95.
37. Smith JS, Green J, Berrington de González A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-67.
38. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085-92.
39. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 1): 72-8.
40. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651.
41. Meirik O, Farley TMM. Risk of cancer and the oral contraceptive pill. BMJ 2007; 335: 621-2.
42. Gallo MF, Grimes DA, Schulz KF, d'Arcangues C, Lopez LM. Combination injectable contraceptives for contraception. Cochrane Database Syst Rev 2005; (3): CD004568.
43. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care 1998; 3: 169-78.
44. van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; (3): CD003553.
45. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74: 439-45.
46. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; (3): CD004695.
47. Richards JS, Russell DL, Ochsner S, Espey LL. Ovulation: new dimensions and new regulators of the Iinflammatory-like response. Annu Rev Physiol 2002; 64: 69-92.
48. Matousek M, Mitsube K, Mikuni M, Brännström M. Inhibition of ovulation in the rat by a leukotriene B4 receptor antagonist. Mol Hum Reprod 2001; 7: 35-42.
49. Peters MW, Pursley JR, Smith GW. Inhibition of intrafollicular PGE2 synthesis and ovulation following ultrasound-mediated intrafollicular injection of the selective cyclooxygenase-2 inhibitor NS-398 in cattle. J Anim Sci 2004; 82: 1656-62.
50. Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2003; (1): CD003552.
51. Kulier R, Helmerhorst FM, O'Brien P, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev 2006; (3): CD005347.
52. O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev 2005; (1): CD003282.
53. Cook L, Nanda K, Grimes D. Diaphragm versus diaphragm with spermicides for contraception. Cochrane Database Syst Rev 2003; (1): CD002031.
54. Gallo MF, Grimes DA, Schulz KF. Cervical cap versus diaphragm for contraception. Cochrane Database Syst Rev 2002; (4): CD003551.
55. Arzneimittelkommission der deutschen Ärzteschaft. "Aus der UAW-Datenbank": Misslungene Explantation des implantierbaren Kontrazeptivums Implanon®. Dt Ärzteblatt 2006; 103: A-1771, B-1519, C-1471.
56. Jacobstein R. Long-acting and permanent contraception: an international development, service delivery perspective. J Midwifery Womens Health 2007; 52: 361-7.
57. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2007; (3): CD001326.
58. Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, Van der Merwe L. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database Syst Rev 2006; (3): CD005214.
59. Grimes DA, Gallo MF, Halpern V, Nanda K, Schulz KF. Fertility awareness-based methods for contraception. Cochrane Database Syst Rev 2004; (4): CD004860.
60. Scott A, Glasier A. Contraceptive sterilization: global issues and trends. Bull World Health Organ 2003; 81: 146.
61. Nardin JM, Kulier R, Boulvain M, Peterson HB. Techniques for the interruption of tubal patency for female sterilisation. Cochrane Database Syst Rev 2002; (4): CD003034.
62. Kulier R, Boulvain M, Walker D, De Candolle G, Campana A. Minilaparotomy and endoscopic techniques for tubal sterilisation. Cochrane Database Syst Rev 2002; (3): CD001328.
63. Update in: Cochrane Database Syst Rev 2004; (3): CD001328.
64. Naz RK, Zhu X, Kadam AL. Identification of human sperm peptide sequence involved in egg binding for immunocontraception. Biol Reprod 2000; 62: 318-24.
65. Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar GP. Recent advances in contraceptive vaccine development: a mini-review. Hum Reprod 2005; 20: 3271-83.
66. Wertheimer RE. Emergency postcoital contraception. Am Fam Physician 2000; 62: 2287-92.
67. Glasier A. Emergency postcoital contraception. N Engl J Med 1997; 337: 1058-64.
68. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999; 353: 697-702.
69. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S, Cheng W, Lüdicke F, Pretnar-Darovec A, Kirkman R, Mittal S, Khomassuridze A, Apter D, Peregoudov A; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803-10.
70. Cheng L, Gülmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev 2004; (3): CD001324.
71. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C; Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367: 1412-20.
72. Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF. Steroid hormones for contraception in men. Cochrane Database Syst Rev 2007; (2): CD004316.
73. Aaltonen P, Amory JK, Anderson RA, Behre HM, Bialy G, Blithe D, Bone W, Bremner WJ, Colvard D, Cooper TG, Elliesen J, Gabelnick HL, Gu YQ, Handelsman DJ, Johansson EA, Kersemaekers W, Liu P, MacKay T, Matlin S, Mbizvo M, McLachlan RI, Meriggiola MC, Mletzko S, Mommers E, Muermans H, Nieschlag E, Odlind V, Page ST, Radlmaier A, Sitruk-Ware R, Swerdloff R, Wang C, Wu F, Zitzmann M. 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl 2007; 28: 362-3.
74. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006; (1): CD003550.
75. Weisek WH. Vasektomie - aktueller Stand. J Reproduktionsmed Endokrinol 2004; 1: 222-7.
76. Labrecque M, Pile J, Sokal D, Kaza RC, Rahman M, Bodh SS, Bhattarai J, Bhatt GD, Vaidya TM. Vasectomy surgical techniques in South and South East Asia. BMC Urol 2005; 5: 10.
77. Cook LA, Van Vliet H, Lopez LM, Pun A, Gallo MF. Vasectomy occlusion techniques for male sterilization. Cochrane Database Syst Rev 2007; (2): CD003991.
78. Cook LA, Pun A, van Vliet H, Gallo MF, Lopez LM. Scalpel versus no-scalpel incision for vasectomy. Cochrane Database Syst Rev 2007; (2): CD004112.
79. Edwards RG. Immunological control of fertility of female mice. Nature 1964; 203: 50-3.
80. Naz RK, Vaneck CM. Testis-specific proteins and their role in contraceptive vaccine development. Front Biosci 1998; 3: 39-48.
81. Kuma TCA. Development of immunocontraceptives: an introduction. Human Reproduction Update 1997; 3: 299-300.
82. O'Rand MG, Widgren EE, Sivashanmugam P, Richardson RT, Hall SH, French FS, VandeVoort CA, Ramachandra SG, Ramesh V, Jagannadha Rao A. Reversible immunocontraception in male monkeys immunized with eppin. Science 2004; 306: 1189-90.
83. Nieschlag E, Henke A. Hopes for male contraception. Lancet 2005; 365: 554-6.
84. Baird DT. Overview of advances in contraception. Br Med Bull 2000; 56: 704-16.
85. Aitken RJ, Paterson M, van Duin M. The potential of the zona pellucida as a target for immunocontraception. Am J Reprod Immunol 1996; 35: 175-80.
86. Aitken RJ. Immunocontraceptive vaccines for human use. J Reprod Immunol 2002; 57: 273.
87. Baird DT, Glasier AF. Science, medicine, and the future. BMJ 1999; 319: 969-72.
88. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995; 87: 827-35.
89. Cameron ST, Thong KJ, Baird DT. Effect of low dose mifepristone on the ovarian cycle and on the dynamics of follicle growth. Clin Endocrinol 1995; 43: 407-14.
90. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stump H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000; 65: 741-51.
91. Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993; 8: 201-7.
92. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 27-242.
93. Lakha F, Ho PC, Van der Spuy ZM, Elton KDR, Glasier AF, Critchley HOD, Williams ARW, Baird DT. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007; 22: 2428-36.
94. Naz RK, Sacco A, Singh O, Pal R, Talwar GP. Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona pellucida) and hormones (human chorionic gonadotropin): current status. Hum Reprod 1995; 1: 1-18.
95. Nieschlag E. "Sixth Summit Meeting Consensus: Recommendations for regulatory approval for hormonal male contraception." Int J Androl 2002; 25: 375.
96. Nieschlag, E, Behre HM (eds). Andrology: Male reproductive health and dysfunction. 2nd ed. Springer, Heidelberg, 2000.
97. Jacobstein R. Long-acting and permanent contraception: an international development, service delivery perspective. J Midwifery Womens Health 2007; 52: 361-7.
98. Scott A, Glasier A. Evidence based contraceptive choices? Best Prac Res Clin Obstet Gynaecol 2006; 20: 665-80.
99. Swerdloff R, Steiner B, Callegari C, Bhasin S. GnRH analogues and male contraception. In: Bhasin S et al (eds). Proceedings of the 2nd International Androgen Workshop. Wiley-Liss, New York, 1995.
100. Ulmann AJ. The development of mifepristone: a pharmaceutical drama in three acts. J Am Med Womens Assoc 2000; 55 (3 Suppl): 117-20.
101. van Vliet HAAM, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; (3): CD002032
102. von Hertzen H, Van Look PFA. Antiprogestins for contraception? Semin Reprod Med 2005; 23: 92-100.
103. Waites GMH. Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil Steril 2003; 80: 1-15.
104. Wassarman PM. Mammalian fertilization: molecular aspects of gamete adhesion, exocytosis, and fusion. Cell 1999; 96: 175-83.
105. Wu X, Viveiros MM, Eppig JJ, Bai Y, Fitzpatrick S, Matzuk MM. Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to-embryo transition. Nat Genet 2003; 33: 187-91.
106. Zhou CX, Zhang YL, Xiao L, Zheng M, Leung KM, Chan MY, LO PS, Tsang LL, Wong HY, Ho LS, Chung YW, Chang HC. An epididymis-specific beta-defensin is important for the initiation of sperm maturation. Nat Cell Biol 2004; 6: 458-64.
107. Cochrane Collaboration Topic: Fertility Regulation. New topic. Contraception related reviews. Abortion related reviews. Review of progestogens in combined oral contraceptives for contraception. http://www.cochrane.org/ reviews/en/topics/64.html
108. Emergency Contraceptive Pills: Medical and service delivery guidelines. Second Edition, 2004. International Consortium for Emergency Contraception, Washington DC, USA. http://www.cecinfo.org/publications/PDFs/resources/ MedicalServiceDeliveryGuidelines_Eng.pdf
109. Kuyoh MA, Toroitich-Ruto C, Grimes DA, Schulz KF, Gallo MF. Sponge versus diaphragm for contraception: a Cochrane review. http://cat.inist.fr/?aModele= afficheN&cpsidt=14469947
110. Population reports: Family planning: a global handbook for providers. Chapter 11: female sterilization. http://www.infoforhealth.org/globalhandbook/ book/fph_chapter11/index.shtml.